{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:42:07Z","timestamp":1790786527002,"version":"4.1.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11940-017-0470-5","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T01:43:17Z","timestamp":1502934197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Botulinum Toxin Treatment in Multiple Sclerosis\u2014a Review"],"prefix":"10.1007","volume":"19","author":[{"given":"Yasaman","family":"Safarpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Jabbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,17]]},"reference":[{"key":"470_CR1","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1212\/WNL.0000000000002469","volume":"86","author":"P Dilokthornsakul","year":"2016","unstructured":"Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86:1014\u201321.","journal-title":"Neurology"},{"issue":"Suppl 5 Improvi","key":"470_CR2","first-page":"S139","volume":"17","author":"HL Zwibel","year":"2011","unstructured":"Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5 Improving):S139\u201345.","journal-title":"Am J Manag Care"},{"key":"470_CR3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3111\/13696998.2013.778268","volume":"16","author":"G Adelman","year":"2013","unstructured":"Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16:639\u201347.","journal-title":"J Med Econ"},{"key":"470_CR4","unstructured":"Botulinum Toxin-Therapeutic clinical practice and science. Jankovic, Albenese, Atassi, Dolly, Hallett, Mayer (Editors). 2009 Sanders-Elsevier Publisher, Philadelphia."},{"key":"470_CR5","doi-asserted-by":"crossref","first-page":"e02131","DOI":"10.1128\/mBio.02131-14","volume":"6","author":"C Montecucco","year":"2015","unstructured":"Montecucco C, Rasotto MB. On botulinum neurotoxin variability. MBio. 2015;6:e02131\u201314.","journal-title":"MBio"},{"key":"470_CR6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","volume":"12","author":"O Rossetto","year":"2014","unstructured":"Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535\u201349.","journal-title":"Nat Rev Microbiol"},{"key":"470_CR7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1212\/WNL.30.12.1303","volume":"30","author":"JW Lance","year":"1980","unstructured":"Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology. 1980;30:1303\u201313.","journal-title":"Neurology"},{"issue":"5","key":"470_CR8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/mus.20284","volume":"31","author":"JM Gracies","year":"2005","unstructured":"Gracies JM. Pathophysiology of spastic paresis. I: paresis and soft tissue changes. Muscle Nerve. 2005;31(5):535\u201351.","journal-title":"Muscle Nerve"},{"issue":"5","key":"470_CR9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mus.20285","volume":"31","author":"JM Gracies","year":"2005","unstructured":"Gracies JM. Pathophysiology of spastic paresis. II: emergence of muscle over activity. Muscle Nerve. 2005;31(5):552\u201371.","journal-title":"Muscle Nerve"},{"issue":"5","key":"470_CR10","first-page":"552","volume":"31","author":"M Gioux","year":"1993","unstructured":"Gioux M, Petit J. Effects of immobilizing the cat peroneus longus muscle on the activity of its own spindles. J Appl Physiol (1985). 1993;31(5):552\u201371.","journal-title":"J Appl Physiol (1985)"},{"issue":"pt 2","key":"470_CR11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/brain\/awg036","volume":"126","author":"C Crone","year":"2003","unstructured":"Crone C, Johnsen LL, Biering-Srensen F, Nielsen JB. Appearance of reciprocal facilitation of ankle extensors from ankle flexors in patients with stroke or spinal cord injury. Brain. 2003;126(pt 2):495\u2013507.","journal-title":"Brain"},{"key":"470_CR12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/practneurol-2011-000155","volume":"12","author":"A Kheder","year":"2012","unstructured":"Kheder A, Nair KPS. Spasticity: pathophysiology, evaluation and management. Pract Neurol. 2012;12:289\u201398.","journal-title":"Pract Neurol"},{"key":"470_CR13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2340\/16501977-0613","volume":"42","author":"AP Yelnik","year":"2010","unstructured":"Yelnik AP, Simon O, Paratte B, et al. How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med. 2010;42:801\u20137.","journal-title":"J Rehabil Med"},{"issue":"12 Supple","key":"470_CR14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/14737175.2013.865877","volume":"13","author":"C Pozzilli","year":"2013","unstructured":"Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother. 2013;13(12 Supple):49\u201354.","journal-title":"Expert Rev Neurother"},{"key":"470_CR15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","volume":"10","author":"MA Rizzo","year":"2004","unstructured":"Rizzo MA. Hadjimichael OC, preingerova J, Vollmer TL, prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589\u201395.","journal-title":"Mult Scler"},{"issue":"12","key":"470_CR16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s12325-009-0082-x","volume":"26","author":"HL Zwibel","year":"2009","unstructured":"Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26(12):1043\u201357.","journal-title":"Adv Ther"},{"key":"470_CR17","first-page":"111","volume":"10","author":"A Martin","year":"2014","unstructured":"Martin A, Abogunrin S, Kurth H, Dinet J. Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatr Dis Treat. 2014;10:111\u201322.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"470_CR18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ane.12202","volume":"129","author":"P Flachenecker","year":"2014","unstructured":"Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis\u2014clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129(3):154\u201362.","journal-title":"Acta Neurol Scand"},{"key":"470_CR19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.410280407","volume":"28","author":"BJ Snow","year":"1990","unstructured":"Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512\u20135.","journal-title":"Ann Neurol"},{"key":"470_CR20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.45.4.712","volume":"45","author":"MA Grazko","year":"1995","unstructured":"Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995;45:712\u20137.","journal-title":"Neurology"},{"key":"470_CR21","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707\u201312. This is the first double blind, placebo controlled study which demonstrated improvement of adductor spasticity after BoNT therapy in a sizeable number of patients with multiple sclerosis.","DOI":"10.1136\/jnnp.68.6.707"},{"key":"470_CR22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.pmrj.2013.11.001","volume":"6","author":"CP Phadke","year":"2014","unstructured":"Phadke CP, Davidson C, Ismail F, Boulias C. The effect of neural lesion type on botulinum toxin dosage: a retrospective chart review. PM R. 2014;6:406\u201311.","journal-title":"PM R"},{"key":"470_CR23","doi-asserted-by":"crossref","unstructured":"Schramm A, Ndayisaba JP, Auf dem Brinke M, Hecht M, Herrmann C, Huber M, et al. Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry. J Neural Transm (Vienna). 2014;121:521\u201330.","DOI":"10.1007\/s00702-013-1145-3"},{"key":"470_CR24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.urology.2014.07.046","volume":"84","author":"U Nuanthaisong","year":"2014","unstructured":"Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014;84:1044\u20138.","journal-title":"Urology"},{"key":"470_CR25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00415-016-8304-z","volume":"264","author":"D Dressler","year":"2017","unstructured":"\u2022 Dressler D, Bhidayasiri R, Bohlega S. Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J Neurol. 2017;264:112\u201320. This recent publication indicates that a European task force after reviewing world literature recommends BoNT therapy for treatment of spasticity in multiple sclerosis.","journal-title":"J Neurol"},{"key":"470_CR26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7224\/1537-2073.2012-031","volume":"15","author":"GJ Yonnet","year":"2013","unstructured":"Yonnet GJ, Fjeldstad AS, Carlson NG, Rose JW. Advances in the Management of Neurogenic detrusor overactivity in multiple sclerosis. Int J MS Case. 2013;15:66\u201372.","journal-title":"Int J MS Case"},{"key":"470_CR27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0079-6123(08)63057-5","volume":"87","author":"G Holstege","year":"1991","unstructured":"Holstege G. Descending motor pathways and spinal motor system. Limbic and non-limbic components. Prog Brain research. 1991;87:307\u2013421.","journal-title":"Prog Brain research"},{"key":"470_CR28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrurol.2015.266","volume":"12","author":"D Griffiths","year":"2015","unstructured":"Griffiths D. Neural control of micturition in humans: a working model. Nat Rev Urol. 2015;12:695\u2013705.","journal-title":"Nat Rev Urol"},{"key":"470_CR29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000353274","volume":"41","author":"A Ruffion","year":"2013","unstructured":"Ruffion A, Castro-Diaz D, Patel H, Khalaf K, Onyenwenyi A, Globe D, et al. Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder. Neuroepidemiology. 2013;41:146\u201355.","journal-title":"Neuroepidemiology"},{"key":"470_CR30","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.juro.2009.12.029","volume":"183","author":"ST Mahajan","year":"2010","unstructured":"Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS patient registry. J Urol. 2010;183:1432\u20137.","journal-title":"J Urol"},{"key":"470_CR31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0036-1582255","volume":"36","author":"A Wintner","year":"2016","unstructured":"Wintner A, Kim MM, Bechis SK, Kreydin EI. Voiding dysfunction in multiple sclerosis. Semin Neurol. 2016;36:34\u201340.","journal-title":"Semin Neurol"},{"key":"470_CR32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","volume":"13","author":"M S\u00e8ze de","year":"2007","unstructured":"de S\u00e8ze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B, GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13:915\u201328.","journal-title":"Mult Scler"},{"key":"470_CR33","first-page":"470","volume":"80","author":"CJ Fowler","year":"2009","unstructured":"Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80:470\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"470_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.1967.sp008119","volume":"188","author":"FG Carpenter","year":"1967","unstructured":"Carpenter FG. Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rats. J Physiol. 1967;188:1\u201311.","journal-title":"J Physiol"},{"key":"470_CR35","first-page":"375","volume":"96","author":"B Schurch","year":"1990","unstructured":"Schurch B, Hauri D, Largo M, Kreienb\u00fchl B, Meyer E, Rossier AB. Effects of botulinum A toxin on the periurethral striated sphincter of the neurogenic bladder. Preliminary study. J Urol (Paris). 1990;96:375\u201380.","journal-title":"J Urol (Paris)"},{"key":"470_CR36","first-page":"24","volume":"71","author":"DD Dykstra","year":"1990","unstructured":"Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71:24\u20136.","journal-title":"Arch Phys Med Rehabil"},{"key":"470_CR37","doi-asserted-by":"crossref","unstructured":"Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742\u201350.","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"470_CR38","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131\u20139. This phase 3 blinded study shows efficacy, safety and tolerability of OnaBoNT-A treatment in improving bladder symptoms of detrusor hyperactivity in multiple sclerosis.","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"470_CR39","doi-asserted-by":"crossref","unstructured":"Schurch B, de S\u00e8ze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botox detrusor hyperreflexia study team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196\u2013200.","DOI":"10.1097\/01.ju.0000162035.73977.1c"},{"key":"470_CR40","doi-asserted-by":"crossref","unstructured":"Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. Efficacy of botulinum toxin a injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229\u201335.","DOI":"10.1016\/j.juro.2011.02.004"},{"key":"470_CR41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/nau.22293","volume":"32","author":"D Sussman","year":"2013","unstructured":"Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32:242\u20139.","journal-title":"Neurourol Urodyn"},{"key":"470_CR42","doi-asserted-by":"crossref","unstructured":"Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, Picaut P; Dysport Study Group. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport\u00ae (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2016;36:457\u201362","DOI":"10.1002\/nau.22954"},{"key":"470_CR43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0035-1571216","volume":"36","author":"CP Smith","year":"2016","unstructured":"Smith CP, Chancellor MB. Botulinum toxin to treat neurogenic bladder. Semin Neurol. 2016;36:5\u20139.","journal-title":"Semin Neurol"},{"key":"470_CR44","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/jnnp.2004.045765","volume":"76","author":"P Gallien","year":"2005","unstructured":"Gallien P, Reymann JM, Amarenco G, Nicolas B, de S\u00e8ze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76:1670.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"470_CR45","doi-asserted-by":"crossref","unstructured":"Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013;154:632\u201342.","DOI":"10.1016\/j.pain.2012.12.002"},{"key":"470_CR46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00415-012-6579-2","volume":"260","author":"A Truini","year":"2013","unstructured":"Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260:351\u201367.","journal-title":"J Neurol"},{"key":"470_CR47","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11916-010-0108-8","volume":"14","author":"TJ Nurmikko","year":"2010","unstructured":"Nurmikko TJ, Gupta S, Maclver K. Multiple sclerosis-related central pain disorders. Curr Pain Headache Rep. 2010;14:189\u201395.","journal-title":"Curr Pain Headache Rep"},{"key":"470_CR48","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1191\/1352458505ms1177oa","volume":"11","author":"AH Al-Araji","year":"2005","unstructured":"Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005;11:398\u2013402.","journal-title":"Mult Scler"},{"key":"470_CR49","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1177\/0333102411424619","volume":"31","author":"D Mueller","year":"2011","unstructured":"Mueller D, Obermann M, Yoon MS, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia. 2011;31:1542\u20138.","journal-title":"Cephalalgia"},{"key":"470_CR50","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1227\/01.NEU.0000137656.59536.0E","volume":"55","author":"G Broggi","year":"2004","unstructured":"Broggi G, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery. 2004;55:830\u20138. discussion 838\u2013839","journal-title":"Neurosurgery"},{"key":"470_CR51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000110284","volume":"10","author":"S Katusic","year":"1991","unstructured":"Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology. 1991;10:276\u201381.","journal-title":"Neuroepidemiology"},{"key":"470_CR52","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/WNL.0000000000002840","volume":"87","author":"G Cruccu","year":"2016","unstructured":"Cruccu G, Finnerup NB, Jensen TS, Scholz J, Sindou M, Svensson P, et al. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. Neurology. 2016;87:220\u20138.","journal-title":"Neurology"},{"key":"470_CR53","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1468-1331.2008.02185.x","volume":"15","author":"G Cruccu","year":"2008","unstructured":"Cruccu G, Gronseth G, Alksne J, et al. AANEFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013\u201328.","journal-title":"Eur J Neurol"},{"issue":"16","key":"470_CR54","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1242\/jcs.012211","volume":"120","author":"J Meng","year":"2007","unstructured":"Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120(16):2864\u201374.","journal-title":"J Cell Sci"},{"key":"470_CR55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","volume":"107","author":"M Cui","year":"2004","unstructured":"Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125\u201333.","journal-title":"Pain"},{"key":"470_CR56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1254\/jphs.11060FP","volume":"118","author":"MC Shin","year":"2012","unstructured":"Shin MC, Wakita M, Xie DJ, et al. Inhibition of membrane Na+ channels by a type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J Pharmacol Sci. 2012;118:33\u201342.","journal-title":"J Pharmacol Sci"},{"key":"470_CR57","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/j.1526-4637.2010.01003.x","volume":"11","author":"L Xiao","year":"2010","unstructured":"Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin A is beneficial in Postherpetic neuralgia. Pain Med. 2010;11:1827\u201333.","journal-title":"Pain Med"},{"key":"470_CR58","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","volume":"64","author":"DA Ranoux","year":"2008","unstructured":"Ranoux DA, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274\u201383.","journal-title":"Ann Neurol"},{"key":"470_CR59","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/01.wnl.0000345968.05959.cf","volume":"72","author":"RY Yuan","year":"2009","unstructured":"Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72:1473\u20138.","journal-title":"Neurology"},{"key":"470_CR60","doi-asserted-by":"crossref","unstructured":"Wu CJ, Lian YJ, Zheng YK, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32:443\u201350.","DOI":"10.1177\/0333102412441721"},{"key":"470_CR61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/WNF.0b013e31829cb60e","volume":"36","author":"C Zuniga","year":"2013","unstructured":"Zuniga C, Piedimonte F, Diaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol. 2013;36:146\u201350.","journal-title":"Clin Neuropharmacol"},{"key":"470_CR62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1129-2377-14-92","volume":"14","author":"HS Shehata","year":"2013","unstructured":"Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013;14:92.","journal-title":"J Headache Pain."},{"key":"470_CR63","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1129-2377-15-65","volume":"15","author":"H Zhang","year":"2014","unstructured":"Zhang H, Lian Y, Ma Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014;15:65.","journal-title":"J Headache Pain"},{"key":"470_CR64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1017\/cjn.2015.321","volume":"43","author":"A Shaikh","year":"2016","unstructured":"Shaikh A, Phadke CP, Ismail F, Boulias C. Relationship between botulinum toxin, spasticity, and pain: a survey of patient perception. Can J Neurol Sci. 2016;43:311\u20135.","journal-title":"Can J Neurol Sci."},{"key":"470_CR65","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2340\/16501977-0066","volume":"39","author":"E Marco","year":"2007","unstructured":"Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. Rehabil Med. 2007;39:440\u20137.","journal-title":"Rehabil Med"},{"key":"470_CR66","doi-asserted-by":"crossref","unstructured":"Shaw LC, Price CI, Van Wijck FM, Shackley P, Steen N, Barnes MP, et al., BoTULS investigators. Botulinum toxin for the upper limb after stroke (BoTULS) trial: effect on impairment, activity limitation, and pain. Stroke. 2011;42:1371\u20139.","DOI":"10.1161\/STROKEAHA.110.582197"},{"key":"470_CR67","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/1545968311430824","volume":"26","author":"RL Rosales","year":"2012","unstructured":"Rosales RL, Kong KH, Goh KJ, Kumthornthip W, Mok VC, Delgado-De Los Santos MM, et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2012;26:812\u201321.","journal-title":"Neurorehabil Neural Repair"},{"key":"470_CR68","doi-asserted-by":"crossref","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al., PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921\u201336.","DOI":"10.1111\/j.1526-4610.2010.01678.x"},{"key":"470_CR69","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.pain.2013.07.050","volume":"154","author":"X Moisset","year":"2013","unstructured":"Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P. Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. Pain. 2013;154:2691\u20139.","journal-title":"Pain"},{"key":"470_CR70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.msard.2012.10.003","volume":"2","author":"AA Gelfand","year":"2013","unstructured":"Gelfand AA, Gelfand JM, Goadsby PJ. Migraine and multiple sclerosis: epidemiology and approach to treatment. Mult Scler Relat Disord. 2013;2:73\u20139.","journal-title":"Mult Scler Relat Disord"},{"key":"470_CR71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archneur.1974.00490310049008","volume":"30","author":"H Shibasaki","year":"1974","unstructured":"Shibasaki H, Kuroiwa Y. Painful tonic seizures in multiple sclerosis. Arch Neurol. 1974;30:47\u201351.","journal-title":"Arch Neurol"},{"key":"470_CR72","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1212\/01.WNL.0000080081.74117.E4","volume":"61","author":"DA Restivo","year":"2003","unstructured":"Restivo DA, Tinazzi M, Patti F, Palmeri A, Maimone D. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003;61:719\u201320.","journal-title":"Neurology"},{"key":"470_CR73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.7224\/1537-2073.2015-008","volume":"18","author":"W Meador","year":"2016","unstructured":"Meador W, Salter AR, Rinker JR II. Symptomatic management of multiple sclerosis-associated tremor among participants in the NARCOMS registry. Int J MS Care. 2016;18:147\u201353.","journal-title":"Int J MS Care"},{"key":"470_CR74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00415-006-0296-7","volume":"254","author":"M Koch","year":"2007","unstructured":"Koch M, Mostert J, Heersema D, et al. Tremor in multiple sclerosis. J Neurol. 2007;254:133\u201345.","journal-title":"J Neurol"},{"key":"470_CR75","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/archneur.1984.04050150058017","volume":"41","author":"WC Koller","year":"1984","unstructured":"Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol. 1984;41:280\u20131.","journal-title":"Arch Neurol"},{"key":"470_CR76","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.870110306","volume":"11","author":"J Jankovic","year":"1996","unstructured":"Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11:250\u20136.","journal-title":"Mov Disord"},{"key":"470_CR77","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1017\/S031716710001489X","volume":"40","author":"F Rahimi","year":"2013","unstructured":"Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P, Jog M. Effectiveness of BoNT A in Parkinson's disease upper limb tremor management. Can J Neurol Sci. 2013;40:663\u20139.","journal-title":"Can J Neurol Sci"},{"key":"470_CR78","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1468-1331.1997.tb00301.x","volume":"4","author":"CE Clarke","year":"1997","unstructured":"Clarke CE. Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis. Eur J Neurol. 1997;4:68\u201371.","journal-title":"Eur J Neurol"},{"key":"470_CR79","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00415-004-0331-5","volume":"251","author":"L Gutmann","year":"2004","unstructured":"Gutmann L, Gutmann L. Myokymia and neuromyotonia. J Neurol. 2004;251:138\u201342.","journal-title":"J Neurol"},{"key":"470_CR80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/brain\/84.1.31","volume":"84","author":"F Andermann","year":"1961","unstructured":"Andermann F, Cosgrove JBR, Lloyd-Smith DL, Gloor P, McNaughton FL. Facial myokymia in multiple sclerosis. Brain. 1961;84:31\u201344.","journal-title":"Brain"},{"key":"470_CR81","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archneur.1994.00540230053012","volume":"51","author":"L Jacobs","year":"1994","unstructured":"Jacobs L, Kaba S, Pullicino P. The lesion causing continuous facial myokymia in multiple sclerosis. Arch Neurol. 1994;51:1115\u20139.","journal-title":"Arch Neurol"},{"key":"470_CR82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000008152","volume":"43","author":"MJ Sedano","year":"2000","unstructured":"Sedano MJ, Trejo JM, Macarr\u00f3n JL, Polo JM, Berciano J, Calleja J. Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin. Eur Neurol. 2000;43:137\u201340.","journal-title":"Eur Neurol"},{"key":"470_CR83","first-page":"26","volume":"36","author":"L Gutmann","year":"1986","unstructured":"Gutmann L, Brick JF, Riggs JE. Calcium and myokymia of brainstem origin. Neurology. 1986;36:26\u201330.","journal-title":"Neurology"},{"key":"470_CR84","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s13760-012-0092-3","volume":"112","author":"M Habek","year":"2012","unstructured":"Habek M, Adamec I, Gabeli\u0107 T, Brinar VV. Treatment of facial myokymia in multiple sclerosis with botulinum toxin. Acta Neurol Belg. 2012;112:423\u20134.","journal-title":"Acta Neurol Belg"},{"key":"470_CR85","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1468-1331.2010.03189.x","volume":"18","author":"DA Restivo","year":"2011","unstructured":"\u2022 Restivo DA, Marchese-Ragona R, Patti F, Solaro C, Maimone D, Zappal\u00e1 G, et al. Botulinum toxin improves dysphagia associated with multiple sclerosis. Eur J Neurol. 2011;18:486\u201390. This prospective open label study demonstrates that injection of BoNTs into the cricoesophageal muscle can improve spastic dysphagia in patients with multiple sclerosis.","journal-title":"Eur J Neurol"},{"key":"470_CR86","doi-asserted-by":"publisher","unstructured":"Alfonsi E, Restivo DA, Cosentino G, et al. Botulinum toxin is effective in the Management of Neurogenic Dysphagia.Clinical-electrophysiological findings and tips on safety in different eurological disorders. Front Pharmacol. 2017;8:80. doi: 10.3389\/fphar.2017.00080 . eCollection 2017","DOI":"10.3389\/fphar.2017.00080"},{"key":"470_CR87","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaapos.2007.03.005","volume":"11","author":"R Murthy","year":"2007","unstructured":"Murthy R, Dawson E, Khan S, Adams GG, Lee J. Botulinum toxin in the management of internuclear ophthalmoplegia. J AAPOS. 2007;11:456\u20139.","journal-title":"J AAPOS"},{"key":"470_CR88","doi-asserted-by":"crossref","unstructured":"Hosp C, Naumann MK, Hamm H. Botulinum toxin treatment of autonomic disorders: focal hyperhidrosis and sialorrhea. Semin Neurol. 2016;36:20\u20138.","DOI":"10.1055\/s-0035-1571214"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-017-0470-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0470-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0470-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T09:46:36Z","timestamp":1570009596000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-017-0470-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,17]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["470"],"URL":"https:\/\/doi.org\/10.1007\/s11940-017-0470-5","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,17]]},"article-number":"33"}}